Feedback

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients

Affiliation
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy and School of Pharmacy ,Xuzhou Medical University ,Xuzhou ,China
Wang, Dong-Dong;
Affiliation
Department of Pharmacy ,Xuzhou Oriental Hospital Affiliated to Xuzhou Medical University ,Xuzhou ,China
Zhang, Cun;
Affiliation
Department of Endocrinology ,Huaian Hospital of Huaian City ,Huaian ,China
Zhu, Ping;
Affiliation
Department of Pharmacy ,Suzhou Science and Technology Town Hospital ,Suzhou ,China
He, Su-Mei;
Affiliation
School of Nursing ,Xuzhou Medical University ,Xuzhou ,China
Chen, Xiao

The aim of the present study is to investigate the quantitative effects of sodium–glucose cotransporter-2 (SGLT-2) inhibitors on the quality of life in heart failure (HF) patients. A total of 14,674 HF patients from two dapagliflozin and three empagliflozin studies is included for analysis via the nonlinear mixed-effect modeling (NONMEM) software, among which the change rate of the Kansas City Cardiomyopathy Questionnaire (KCCQ) score is used as the evaluation index. There is no significant difference in the pharmacodynamics influencing the quality of life in HF patients between the SGLT-2 inhibitors: 10 mg/day dapagliflozin and 10 mg/day empagliflozin. For the clinical summary score (CSS), total symptom score (TSS), and overall summary score (OSS), the E max of the SGLT-2 inhibitors on the quality of life in HF patients is 3.74%, 4.43%, and 4.84%, respectively, and ET 50 is 2.23, 4.37, and 7.15 weeks, respectively. In addition, the time duration of achieving 25%, 50%, 75%, and 80% E max is 0.75, 2.23, 6.69, and 8.92 weeks for the CSS; 1.46, 4.37, 13.11, and 17.48 weeks for the TSS; and 2.39, 7.15, 21.45, and 28.6 weeks for the OSS, respectively. Therefore, to reach the plateau period (80% of E max ) of SGLT-2 inhibitors on the CSS, TSS, and OSS, 10 mg/day dapagliflozin (or 10 mg/day empagliflozin) is required to be taken for 8.92 weeks, 17.48 weeks, and 28.6 weeks, respectively. This is the first time that the quantitative effects of SGLT-2 inhibitors on the quality of life in HF patients are being explored.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2022 Wang, Zhang, Zhu, He and Chen.

Use and reproduction: